Although blocking the interaction of interleukin 8 with CXCR1 and CXCR2 enhanced lapatinib-inhibited CSC activity and suppressed tumor growth in a xenograft mouse model, concern remains that targeting individual GPCRs may not be effective for eradicating CSCs [21,52]. The gene discussed is CXCR2; the disease is neoplasm.